Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Active psoriatic arthritis in adult patients who have had inadequate response or who have been intolerant to prior DMARD therapy. Moderate to severe palmoplantar pustulosis in adult patients who do not adequately respond to conventional therapy.
Plaque psoriasis & palmoplantar pustulosis 100 mg SC inj at wk 0, wk 4 & every 8 wk thereafter. Psoriatic arthritis 100 mg SC inj at wk 0 & 4, followed by maintenance dose every 8 wk. Patient at high risk of joint damage 100 mg every 4 wk may be considered.
Infections, do not initiate in patients w/ any clinically important active infection. Pre-treatment evaluation for TB. Immunizations, to complete all age appropriate immunizations prior to initiating therapy. Discontinue use if hypersensitivity reactions occur. Hepatic transaminase elevations, to evaluate liver enzymes at baseline & thereafter according to routine patient management. Pregnancy & lactation.
Sign Out
